Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump Says Anthropic No Longer Seen as National Security Threat 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
WALTHAM, Mass., Feb. 03, 2016 -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, President and COO of TESARO, will present at the Leerink Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria in New York City on February 10, 2016 at 2:40 PM Eastern time.
A live webcast of this presentation will be accessible via the Investors page of the TESARO website at www.tesarobio.com. An archived replay of the webcast will be available on the Company’s website for 14 days following the conference.
About TESARO
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
